
Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.
In an interview with Bloomberg News, Viehbacher likened the future of Alzheimer’s treatment to other complex diseases that require multiple drugs with different mechanisms of action.